Literature DB >> 24398371

Extracellular vesicle-derived CD14 is independently associated with the extent of cardiovascular disease burden in patients with manifest vascular disease.

Joyce E P Vrijenhoek1, Gerard Pasterkamp2, Frans L Moll2, Gert Jan de Borst2, Michiel L Bots2, Louise Catanzariti2, Sander M van de Weg2, Dominique P V de Kleijn3, Frank L J Visseren2, Hester M Den Ruijter2.   

Abstract

BACKGROUND: In patients with established cardiovascular disease, high levels of the extracellular vesicle (EV)-derived proteins cystatin C, CD14, and α2-antiplasmin predict recurrent cardiovascular events. We examined whether these proteins are associated with the extent of vascular disease.
METHODS: In 1062 patients from the SMART (Secondary Manifestations in ARTerial disease) study, EVs were isolated from plasma at baseline. Cystatin C, CD14, and α2-antiplasmin were measured in these vesicles using a multiplex assay. The extent of vascular disease burden was determined by a sum score that incorporates history and current presence of clinically manifest coronary, cerebrovascular, peripheral arterial, and abdominal aneurysm disease, and parameters of atherosclerosis that were assessed during the SMART screening protocol (ankle-brachial index, common carotid intima-media thickness, carotid stenosis, and aorta diameter). The relation between EV protein levels and extent of vascular disease was evaluated using ordinal multivariable regression models.
RESULTS: EV-derived CD14 was significantly associated with the number of affected vascular territories (OR 2.4, 95% CI 1.4-4.1) as represented by the sum score, independently of cardiovascular risk factors. Cystatin C and α2-antiplasmin EV levels did not show an independent association with vascular disease extent. When investigating parameters of the sum score separately, we did not observe a strong association between any of the EV-derived proteins and the markers of atherosclerosis.
CONCLUSIONS: EV-derived CD14 levels are strongly correlated to the extent of vascular disease, but not specifically to markers that reflect atherosclerosis burden, in patients with manifest cardiovascular disease. © The European Society of Cardiology 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Atherosclerosis; biomarkers; peripheral vascular diseases; protein

Mesh:

Substances:

Year:  2014        PMID: 24398371     DOI: 10.1177/2047487313518478

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  11 in total

1.  Secreted Monocyte miR-27a, via Mesenteric Arterial Mas Receptor-eNOS Pathway, Causes Hypertension.

Authors:  Xue Zou; Jialiang Wang; Caiyu Chen; Xiaorong Tan; Yu Huang; Pedro A Jose; Jian Yang; Chunyu Zeng
Journal:  Am J Hypertens       Date:  2020-01-01       Impact factor: 2.689

2.  Inflammation, Senescence and MicroRNAs in Chronic Kidney Disease.

Authors:  Andres Carmona; Fatima Guerrero; Maria Jose Jimenez; Francisco Ariza; Marisa L Agüera; Teresa Obrero; Victoria Noci; Juan Rafael Muñoz-Castañeda; Mariano Rodríguez; Sagrario Soriano; Juan Antonio Moreno; Alejandro Martin-Malo; Pedro Aljama
Journal:  Front Cell Dev Biol       Date:  2020-08-06

Review 3.  Extracellular Vesicles as Messengers in Atherosclerosis.

Authors:  Mengna Peng; Xinfeng Liu; Gelin Xu
Journal:  J Cardiovasc Transl Res       Date:  2019-10-29       Impact factor: 4.132

4.  Association of CD14 with incident dementia and markers of brain aging and injury.

Authors:  Matthew P Pase; Jayandra J Himali; Alexa S Beiser; Charles DeCarli; Emer R McGrath; Claudia L Satizabal; Hugo J Aparicio; Hieab H H Adams; Alexander P Reiner; W T Longstreth; Myriam Fornage; Russell P Tracy; Oscar Lopez; Bruce M Psaty; Daniel Levy; Sudha Seshadri; Joshua C Bis
Journal:  Neurology       Date:  2019-12-09       Impact factor: 9.910

5.  Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease.

Authors:  Davide Povero; Akiko Eguchi; Hongying Li; Casey D Johnson; Bettina G Papouchado; Alexander Wree; Karen Messer; Ariel E Feldstein
Journal:  PLoS One       Date:  2014-12-03       Impact factor: 3.240

6.  BLTR1 and CD36 Expressing Microvesicles in Atherosclerotic Patients and Healthy Individuals.

Authors:  Mathilde Sanden; Jaco Botha; Michael René Skjelbo Nielsen; Morten Hjuler Nielsen; Erik Berg Schmidt; Aase Handberg
Journal:  Front Cardiovasc Med       Date:  2018-10-30

Review 7.  Extracellular Vesicles in Diagnosing Chronic Coronary Syndromes the Bumpy Road to Clinical Implementation.

Authors:  Mirthe Dekker; Farahnaz Waissi; Nathalie Timmerman; Max J M Silvis; Leo Timmers; Dominique P V de Kleijn
Journal:  Int J Mol Sci       Date:  2020-11-30       Impact factor: 5.923

8.  Functional and transcriptomic analysis of extracellular vesicles identifies calprotectin as a new prognostic marker in peripheral arterial disease (PAD).

Authors:  Goren Saenz-Pipaon; Patxi San Martín; Núria Planell; Alberto Maillo; Susana Ravassa; Amaia Vilas-Zornoza; Esther Martinez-Aguilar; José Antonio Rodriguez; Daniel Alameda; David Lara-Astiaso; Felipe Prosper; José Antonio Paramo; Josune Orbe; David Gomez-Cabrero; Carmen Roncal
Journal:  J Extracell Vesicles       Date:  2020-02-19

Review 9.  Extracellular vesicle signalling in atherosclerosis.

Authors:  E Charla; J Mercer; P Maffia; S A Nicklin
Journal:  Cell Signal       Date:  2020-08-26       Impact factor: 4.315

Review 10.  Exploring New Kingdoms: The Role of Extracellular Vesicles in Oxi-Inflamm-Aging Related to Cardiorenal Syndrome.

Authors:  Cristina Mas-Bargues; Matilde Alique; María Teresa Barrús-Ortiz; Consuelo Borrás; Raquel Rodrigues-Díez
Journal:  Antioxidants (Basel)       Date:  2021-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.